Strata Critical Medical AI Stock Analysis
Want to see SRTA full AI Analyst Report?
Strata Critical Medical (SRTA) AI Stock Analysis
Strata Critical Medical
(NASDAQ:SRTA)
SRTA’s score is driven primarily by improving operations and upbeat, reaffirmed guidance from the earnings call, plus a very strong low-debt balance sheet. Offsetting this, current TTM profitability is still negative with only marginal free cash flow, technical momentum is mixed (negative MACD), and valuation is hampered by losses (negative P/E) with no dividend support.
Strata Critical Medical (SRTA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $468.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 982.38K
- Price to Earnings (P/E)
- -17.1
- Beta (1Y)
- 1.89
- Revenue Growth
- 22.73%
- EPS Growth
- 3.40%
- Country
- US
- Employees
- 327
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Strata Critical Medical Business Overview & Revenue Model
Company Description
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of hum...
Strata Critical Medical Earnings Call Summary
The call was strongly positive overall. Highlights included substantial revenue, EBITDA, margin and free cash flow growth; continued clinical market-share gains; early achievement of the logistics margin target; strong liquidity; acquisition capacity; and a new share repurchase authorization. The company did face seasonal transplant declines, shorter logistics distances, lower logistics revenue and year-over-year logistics gross margin, a sequential decline in clinical gross margin, elevated stock-based compensation and a GAAP loss caused by noncash items. However, management reiterated 2026 guidance and its medium-term growth targets, and the positive operating and strategic developments significantly outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Strata reiterated 2026 guidance for revenue of $285 million to $295 million, adjusted EBITDA of $33 million to $35 million and free cash flow before aircraft and engine acquisitions of $15 million to $22 million; at the midpoint, this implies a low single-digit sequential increase in revenue in the fourth quarter, with Q4 growth driven primarily by clinical, logistics expected to be about flat quarter-over-quarter and gross margin expected to remain about flat sequentially. The company anticipates an increase in clinical gross margins moving into 2027 and remains confident in its medium-term financial targets for high teens organic adjusted EBITDA growth and 30% plus adjusted EBITDA growth, including acquisitions; stock-based compensation expense is expected to decline sequentially approximately 20% to 30% moving into Q4, with the lower run rate expected to persist since 2027, alongside a continued reduction in SG&A as a percentage of revenue.
Strata Critical Medical Financial Statement Overview
Summary
Financials are mixed: revenue is growing (TTM +9.7%) and operating cash flow turned positive ($10.4M), supported by a very low-leverage balance sheet (debt-to-equity ~0.01). However, profitability remains weak (TTM operating and net income still negative; net margin ~-8.8%) and free cash flow is only slightly positive ($0.3M) with uneven conversion, limiting the score despite the strong balance sheet.
Income Statement
34NegativeBalance Sheet
78PositiveCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 280.76M | 197.14M | 248.69M | 225.18M | 146.12M | 50.53M |
| Gross Profit | 57.82M | 41.13M | 58.92M | 42.12M | 22.27M | 10.52M |
| EBITDA | -9.02M | -5.71M | -21.60M | -50.43M | -22.31M | -43.10M |
| Net Income | -24.81M | 41.35M | -27.31M | -56.08M | -27.26M | -40.05M |
Balance Sheet | ||||||
| Total Assets | 328.88M | 325.47M | 256.68M | 294.94M | 325.02M | 335.88M |
| Cash, Cash Equivalents and Short-Term Investments | 41.64M | 61.23M | 127.14M | 166.14M | 192.08M | 281.97M |
| Total Debt | 3.62M | 3.31M | 9.32M | 24.52M | 18.33M | 716.00K |
| Total Liabilities | 52.51M | 46.40M | 34.74M | 60.64M | 50.54M | 44.51M |
| Stockholders Equity | 276.38M | 279.07M | 221.94M | 234.30M | 274.49M | 291.37M |
Cash Flow | ||||||
| Free Cash Flow | 320.00K | -59.92M | -35.51M | -34.46M | -37.86M | -15.91M |
| Operating Cash Flow | 10.39M | -48.91M | -2.52M | -32.35M | -37.13M | -15.62M |
| Investing Cash Flow | 12.57M | 69.75M | -1.02M | 17.09M | 79.34M | -321.34M |
| Financing Cash Flow | -10.58M | -8.91M | -5.76M | -76.00K | -1.08M | 332.26M |
Strata Critical Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTA, the sentiment is Neutral. The current price of 4.96 is below the 20-day moving average (MA) of 5.12, below the 50-day MA of 5.02, and below the 200-day MA of 5.10, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 51.37 is Neutral, neither overbought nor oversold. The STOCH value of 47.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SRTA.
Strata Critical Medical Risk Analysis
Strata Critical Medical disclosed 57 risk factors in its most recent earnings report. Strata Critical Medical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksStrata Critical Medical Peers Comparison
Overall Rating
UHS76Outperform
HCA64Neutral
ARDT63Neutral
SRTA60Neutral
AUNA50Neutral
CYH44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $10.73B | 7.72 | 19.54% | 0.43% | 8.00% | 13.14% | |
| 64Neutral | $99.51B | 15.74 | -100.45% | 0.64% | 5.82% | 16.59% | |
| 63Neutral | $2.03B | 13.85 | 9.48% | ― | 2.03% | -28.50% | |
| 60Neutral | $468.04M | -17.06 | -8.86% | ― | 22.73% | 3.40% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $309.37M | 61.98 | 0.90% | ― | 16.82% | -93.67% | |
| 44Neutral | $284.87M | 6.89 | -2.51% | ― | -7.84% | -88.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SRTA | Strata Critical Medical, Inc. | 4.96 | 0.93 | 23.08% | |
| CYH | Community Health Systems | 1.86 | -1.08 | -36.73% | |
| HCA | Hca Healthcare | 476.35 | 3.31 | 0.70% | |
| UHS | Universal Health Services | 186.07 | -38.33 | -17.08% | |
| AUNA | Auna S.A. Class A | 4.18 | -0.65 | -13.46% | |
| ARDT | Ardent Health Partners, Inc. | 14.40 | 5.76 | 66.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
